BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30486609)

  • 41. Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro.
    Mao HL; Liu PS; Zheng JF; Zhang PH; Zhou LG; Xin G; Liu C
    Pharmacol Res; 2007 Dec; 56(6):483-92. PubMed ID: 18029193
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
    Kantarjian HM; DiNardo CD; Nogueras-Gonzalez GM; Kadia TM; Jabbour E; Bueso-Ramos CE; O'Brien SM; Konopleva M; Jain NB; Daver NG; Shpall EJ; Champlin RE; Simkins A; Garcia-Manero G; Keating MJ; Huang X; Cortes JE; Pierce SA; Ravandi F; Freireich EJ
    Cancer; 2018 Jun; 124(12):2534-2540. PubMed ID: 29645075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functional mutation of SMAC/DIABLO, encoding a mitochondrial proapoptotic protein, causes human progressive hearing loss DFNA64.
    Cheng J; Zhu Y; He S; Lu Y; Chen J; Han B; Petrillo M; Wrzeszczynski KO; Yang S; Dai P; Zhai S; Han D; Zhang MQ; Li W; Liu X; Li H; Chen ZY; Yuan H
    Am J Hum Genet; 2011 Jul; 89(1):56-66. PubMed ID: 21722859
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
    Pardo LM; Voigt AP; Alonzo TA; Wilson ER; Gerbing RB; Paine DJ; Dai F; Menssen AJ; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S; Wells DA; Brodersen LE; Loken MR
    Cytometry B Clin Cytom; 2020 Jan; 98(1):52-56. PubMed ID: 31294507
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma.
    Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kulesza-Bronczyk B; Kinalski M; Terlikowski SJ
    Tumour Biol; 2015 Jun; 36(6):4157-65. PubMed ID: 25577253
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.
    Kim HP; Bernard L; Berkowitz J; Nitta J; Hogge DE
    Cytometry B Clin Cytom; 2012 Sep; 82(5):283-94. PubMed ID: 22508650
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergistic interaction of Smac mimetic and IFNα to trigger apoptosis in acute myeloid leukemia cells.
    Bake V; Roesler S; Eckhardt I; Belz K; Fulda S
    Cancer Lett; 2014 Dec; 355(2):224-31. PubMed ID: 25179908
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia.
    Cheng Z; Dai Y; Pang Y; Jiao Y; Liu Y; Cui L; Quan L; Qian T; Zeng T; Si C; Huang W; Chen J; Pang Y; Ye X; Shi J; Fu L
    J Cell Mol Med; 2020 Jan; 24(1):1067-1075. PubMed ID: 31755224
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TNFAIP8 promotes AML chemoresistance by activating ERK signaling pathway through interaction with Rac1.
    Pang Y; Zhao Y; Wang Y; Wang X; Wang R; Liu N; Li P; Ji M; Ye J; Sun T; Li J; Ma D; Lu F; Ji C
    J Exp Clin Cancer Res; 2020 Aug; 39(1):158. PubMed ID: 32795319
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia.
    Tian Y; Huang Z; Wang Z; Yin C; Zhou L; Zhang L; Huang K; Zhou H; Jiang X; Li J; Liao L; Yang M; Meng F
    PLoS One; 2014; 9(1):e84150. PubMed ID: 24416201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation.
    Jiang A; Jiang H; Brandwein J; Kamel-Reid S; Chang H
    Leuk Res; 2011 Apr; 35(4):492-8. PubMed ID: 20684989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug responsiveness of leukemic cells detected in vitro at diagnosis correlates with therapy response and survival in patients with acute myeloid leukemia.
    Kolesnikova MA; Sen'kova AV; Pospelova TI; Zenkova MA
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1362. PubMed ID: 33675187
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
    DiNardo CD; Lachowiez CA; Takahashi K; Loghavi S; Xiao L; Kadia T; Daver N; Adeoti M; Short NJ; Sasaki K; Wang S; Borthakur G; Issa G; Maiti A; Alvarado Y; Pemmaraju N; Montalban Bravo G; Masarova L; Yilmaz M; Jain N; Andreeff M; Jabbour E; Garcia-Manero G; Kornblau S; Ravandi F; Konopleva MY; Kantarjian HM
    J Clin Oncol; 2021 Sep; 39(25):2768-2778. PubMed ID: 34043428
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TBC1D16 predicts chemosensitivity and prognosis in adult acute myeloid leukemia (AML) patients.
    Liu H; Chen P; Yang YL; Zhu KW; Wang T; Tang L; Liu YL; Cao S; Zhou G; Zeng H; Zhao XL; Zhang W; Chen XP
    Eur J Pharmacol; 2021 Mar; 895():173894. PubMed ID: 33476656
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of CD135/CD117 on Prognosis and Overall Survival of Acute Myeloid Leukemia.
    Raeisi M; Nikhanfar AR; Nejate B; Movassaghpour Akbari AA; Dolatkhah R; Roosta Y; Sanaat Z
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2625-2631. PubMed ID: 31554356
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunosuppressive role of CD11b
    Hyun SY; Na EJ; Jang JE; Chung H; Kim SJ; Kim JS; Kong JH; Shim KY; Lee JI; Min YH; Cheong JW
    Cancer Med; 2020 Oct; 9(19):7007-7017. PubMed ID: 32780544
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML).
    Del Poeta G; Venditti A; Del Principe MI; Maurillo L; Buccisano F; Tamburini A; Cox MC; Franchi A; Bruno A; Mazzone C; Panetta P; Suppo G; Masi M; Amadori S
    Blood; 2003 Mar; 101(6):2125-31. PubMed ID: 12424199
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.
    Pardee TS; Anderson RG; Pladna KM; Isom S; Ghiraldeli LP; Miller LD; Chou JW; Jin G; Zhang W; Ellis LR; Berenzon D; Howard DS; Hurd DD; Manuel M; Dralle S; Lyerly S; Powell BL
    Clin Cancer Res; 2018 May; 24(9):2060-2073. PubMed ID: 29437791
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.